Back to top
more

PetMed Express (PETS)

(Delayed Data from NSDQ)

$3.90 USD

3.90
97,084

+0.04 (1.04%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $3.90 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (54 out of 250)

Industry: Internet - Commerce

Better trading starts here.

Zacks News

Inogen Claims Top Position in Deloitte List on Solid Growth

Inogen's (INGN) unique direct-to-customer business model has lent it a leading position in the United States.

    QIAGEN (QGEN) Faces Declining HPV Sales, Intense Competition

    QIAGEN's (QGEN) top line continues to gain from strength in the Molecular Diagnostics space amid stiff competition and forex woes.

      TransEnterix (TRXC) Posts In-Line Loss in Q3, Sales Fall Y/Y

      TransEnterix's (TRXC) reports unimpressive Q3 results, thanks to the constriction of deferred service revenues.

        Dull MFA & Mineral Nutrition Sales Hurt Phirbo, Rivalry Rife

        Phibro's (PAHC) Medicated feed additives (MFA) business was weak in the United States. Also, a persistent decline in Mineral Nutrition segment sales is likely to raise concern.

          Hologic (HOLX) Q4 Earnings & Revenues Top, Margins Down

          Solid double-digit growth at Hologic's (HOLX) molecular diagnostics and international business drives the top line in Q4.

            Genomic Health (GHDX) Swings to Earnings in Q3, Revenues Lag

            Genomic Health (GHDX) gains from strong adoption of its Oncotype DX test in Q3.

              Hill-Rom (HRC) Banks on Product Launches, Competition Rife

              Hill-Rom (HRC) focuses on product innovation through research and development. A slew of product launches in the fourth quarter is encouraging.

                Amedisys (AMED) Q3 Earnings Beat, Revenues Miss Estimates

                At Hospice division, Amedisys (AMED) registered strong growth across all segments in Q3.

                  Globus Medical (GMED) Q3 Earnings In Line, View Reiterated

                  Globus Medical (GMED) reports in-line third-quarter numbers on the back of higher revenues from core international business.

                    Baxter Posts Solid Q3, Broad Product Spectrum Raises Hopes

                    Baxter's (BAX) convenient kidney dialysis solutions, regenerative tissue products, 3-in-1 oXIRIS set for continuous renal replacement therapy are the latest additions to the extensive product portfolio.

                      SurModics (SRDX) Posts Earnings in Q4, Revenues Top Estimates

                      SurModics' (SRDX) stellar fourth-quarter results benefit from higher product sales, royalties, research, development and other revenues.

                        Haemonetics (HAE) Q2 Earnings Beat Estimates, EPS View Up

                        Continued momentum in new business generation and geographical expansions help Haemonetics (HAE) deliver strong results in Q2.

                          VWR Q3 Earnings Top, Sell-Off to Avantor Approaching Closure

                          VWR's third-quarter report impresses with growth in Americas and EMEA-APAC segments. The transaction with Avantor is also in process.

                            Penumbra (PEN) Posts Earnings, Revenues Top Estimates in Q3

                            Penumbra (PEN) witnesses strong growth across all geographical regions and product lines in Q3.

                              DaVita (DVA) Q3 Earnings Miss & Revenues Beat, '17 View Dull

                              Strong growth in patient services is likely to boost DaVita's (DVA) growth trajectory in the coming quarters. DaVita's (DVA) continuous improvement in Kidney care is commendable as well.

                                Align Technology at 52-Week High: What's Driving the Stock?

                                Align Technology (ALGN) consistently invests in R&D for product innovation.

                                  Myriad Genetics (MYGN) Beats on Q1 Earnings & Revenues

                                  Myriad Genetics (MYGN) rides high on strength in Molecular diagnostics with significant contributions from GeneSight. Also, Hereditary cancer tests continue to witness year-over-year volume growth.

                                    Inogen (INGN) Beats Earnings and Revenue Estimates in Q3

                                    Inogen's (INGN) stellar third-quarter numbers benefit from direct-to-consumer sales and lower cost of goods sold per unit.

                                      Phibro Animal (PAHC) Beats on Q1 Earnings, Reiterates View

                                      Phibro Animal (PAHC) witnesses year-over-year improvement across all segments in Q1.

                                        Wright Medical (WMGI) Portfolio Solid, Lower Extremities Dull

                                        Wright Medical (WMGI) is focusing on product innovation through research and development. However, lackluster international performance of the Lower extremities segment is a matter of concern.

                                          QIAGEN (QGEN) Meets Q3 Earnings, Lags Revenues, Keeps View

                                          QIAGEN's (QGEN) top line gains from strength in the Molecular Diagnostics space in Q3.

                                            Zacks.com featured highlights: PetMed Express, Microsoft, Rockwell Collins, Jones Lang LaSalle and Owens Corning

                                            Zacks.com featured highlights: PetMed Express, Microsoft, Rockwell Collins, Jones Lang LaSalle and Owens Corning

                                              Hill-Rom (HRC) Q4 Earnings and Revenues Top, Margins Up

                                              Hill-Rom (HRC) witnesses strong revenue growth in Q4, driven by a solid momentum in core business, acquisition of Mortara and contribution from product launches.

                                                CVS Health (CVS) Beats Q3 Earnings Estimates, Updates View

                                                CVS Health (CVS) witnesses year-over-year growth in revenues on the back of strength in the Pharmacy Services segment in Q3.

                                                  Henry Schein (HSIC) Misses Q3 Earnings, Margins Decline

                                                  Henry Schein (HSIC) maintains stellar top-line performance in Q3, courtesy of strength in all business segments.